Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Neurology
•
Vascular Neurology
How do you manage acute ischemic stroke patients secondary to HUS/TTP?
Is there a certain platelet value cutoff that you would consider adding antithrombotics?
Related Questions
What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?
Would you consider IV thrombolytics in patients with acute ischemic stroke, with or without a large vessel occlusion, if they have a history of von Willebrand disease (VWD), regardless of its type?
How long would you continue chronic transfusion therapy for adult sickle cell patients who have had a stroke?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
What is the utility of a hypercoagulability workup in recurrent cryptogenic stroke, and what specific tests would you recommend?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How do you manage patients with atrial fibrillation having a thromboembolic infarct despite being on adequate anticoagulation?
How does the presence of signs of cerebral edema influence your decision for thrombolysis and endovascular thrombectomy?
Is there a role for using parenteral anticoagulation for occlusive extensive ICA thrombus with acute onset of symptoms when patients are not candidates for endovascular therapy, such as low NIHSS?
What genetic testing would you consider for recurrent arterial events (cryptogenic strokes, MI) in patients with limited risk factors?